Integra LifeSciences Holdings Co. (NASDAQ:IART) Receives Average Rating of “Reduce” from Brokerages

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) have been assigned an average rating of “Reduce” from the nine ratings firms that are presently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $23.00.

Separately, Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Monday, March 31st.

Hedge Funds Weigh In On Integra LifeSciences

Hedge funds have recently modified their holdings of the stock. Sachem Head Capital Management LP acquired a new position in shares of Integra LifeSciences in the 3rd quarter valued at $44,153,000. Soleus Capital Management L.P. acquired a new position in shares of Integra LifeSciences in the fourth quarter worth about $28,940,000. Paradigm Capital Management Inc. NY increased its position in shares of Integra LifeSciences by 170.3% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company’s stock worth $32,457,000 after acquiring an additional 901,600 shares in the last quarter. Lord Abbett & CO. LLC raised its holdings in shares of Integra LifeSciences by 86.8% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,332,031 shares of the life sciences company’s stock valued at $30,210,000 after acquiring an additional 618,773 shares during the period. Finally, Norges Bank purchased a new stake in shares of Integra LifeSciences in the 4th quarter valued at approximately $8,967,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Stock Performance

Shares of IART opened at $19.57 on Monday. Integra LifeSciences has a 52-week low of $16.81 and a 52-week high of $34.79. The firm has a market capitalization of $1.51 billion, a PE ratio of -217.42, a P/E/G ratio of 0.73 and a beta of 1.24. The firm has a 50-day moving average price of $23.37 and a 200 day moving average price of $22.27. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.12. The business had revenue of $442.65 million for the quarter, compared to analyst estimates of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same quarter last year, the business earned $0.89 earnings per share. On average, sell-side analysts anticipate that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.